Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study.

Date publication

avril 2020

Journal

Annals of oncology : official journal of the European Society for Medical Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BORG Christophe , Dr VERNEREY Dewi , Mme HENRIQUES Julie

Tous les auteurs :
Pagès F, André T, Taieb J, Vernerey D, Henriques J, Borg C, Marliot F, Ben Jannet R, Louvet C, Mineur L, Bennouna J, Desrame J, Faroux R, Kirilovsky A, Duval A, Laurent-Puig P, Svrcek M, Hermitte F, Catteau A, Galon J, Emile JF

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/32294529

Résumé

The Immunoscore (IS), which prognostically classifies stage I-III colon cancer (CC) patients, was evaluated in the IDEA France cohort study investigating 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy in stage III CC patients.

Mots clés

Immunoscore, biomarker, chemotherapy, colon cancer, predictive, prognostic

Référence

Ann. Oncol.. 2020 Apr 12;: